159 related articles for article (PubMed ID: 24788817)
1. Second primary malignancies in patients with neuroendocrine tumors.
Reina JJ; Serrano R; Codes M; Jiménez E; Bolaños M; Gonzalez E; Sevilla I
Clin Transl Oncol; 2014 Oct; 16(10):921-6. PubMed ID: 24788817
[TBL] [Abstract][Full Text] [Related]
2. Metachronous and Synchronous Cancers in Patients with Neuroendocrine Tumors.
Verrico M; Rossi L; Tomao S; Colonna M; Vici P; Tomao F
Oncology; 2020; 98(1):10-15. PubMed ID: 31505502
[TBL] [Abstract][Full Text] [Related]
3. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
Pinto MP; Muñoz Medel M; Carrillo D; Retamal IN; Bravo ML; Valenzuela Y; Nervi B; Sánchez C; Galindo H; Ibañez C; Peña J; Balmaceda C; Madrid J; Briones J; Torres J; Nilo F; Guarda FJ; Quintana JC; Orellana P; Mondaca S; Acevedo F; Vicentini D; Cordova-Delgado M; Owen GI; Garrido M
Horm Cancer; 2019 Feb; 10(1):3-10. PubMed ID: 30465145
[TBL] [Abstract][Full Text] [Related]
4. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours.
Clift AK; Drymousis P; Al-Nahhas A; Wasan H; Martin J; Holm S; Frilling A
Neuroendocrinology; 2015; 102(1-2):26-32. PubMed ID: 25824138
[TBL] [Abstract][Full Text] [Related]
6. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R
Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156
[TBL] [Abstract][Full Text] [Related]
7. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors.
Kauffmann RM; Wang L; Phillips S; Idrees K; Merchant NB; Parikh AA
Ann Surg Oncol; 2014 Oct; 21(11):3422-8. PubMed ID: 25059786
[TBL] [Abstract][Full Text] [Related]
8. Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry.
Palepu J; Shrikhande SV; Bhaduri D; Shah RC; Sirohi B; Chhabra V; Dhar P; Sastry R; Sikora S
Indian J Gastroenterol; 2017 Nov; 36(6):445-451. PubMed ID: 29457213
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
10. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
11. Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018.
Yang Z; Liu L; Leng K; Shi G
J Gastroenterol Hepatol; 2023 Sep; 38(9):1474-1484. PubMed ID: 37114675
[TBL] [Abstract][Full Text] [Related]
12. Risk prediction of second primary malignancies in primary colorectal neuroendocrine neoplasms patients: a population-based study.
Ding X; Yang X; Hao Q; Xu F; Yu X; Rao L; Yuan C; Tian S
J Endocrinol Invest; 2023 Sep; 46(9):1881-1889. PubMed ID: 36870016
[TBL] [Abstract][Full Text] [Related]
13. The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database.
Bu X; Wang X; Wei L; Liu J; Chen M
Curr Probl Cancer; 2020 Dec; 44(6):100613. PubMed ID: 32563531
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine tumors and second primary malignancy--a relationship with clinical impact?
Prommegger R; Ensinger C; Steiner P; Sauper T; Profanter C; Margreiter R
Anticancer Res; 2004; 24(2C):1049-51. PubMed ID: 15154621
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
16. The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study.
Stemann Lau T; Dam G; Jepsen P; Grønbæk H; Krogh K; Gregersen T
Neuroendocrinology; 2018; 107(3):280-283. PubMed ID: 30092588
[TBL] [Abstract][Full Text] [Related]
17. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.
Lyubimova NV; Churikova TK; Kushlinskii NE
Bull Exp Biol Med; 2016 Mar; 160(5):702-4. PubMed ID: 27021085
[TBL] [Abstract][Full Text] [Related]
19. Primary small intestinal neuroendocrine tumors are highly prevalent and often multiple before metastatic disease develops.
Eriksson J; Norlén O; Ögren M; Garmo H; Ihre-Lundgren C; Hellman P
Scand J Surg; 2021 Mar; 110(1):44-50. PubMed ID: 31587594
[TBL] [Abstract][Full Text] [Related]
20. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006.
Navalkele P; O'Dorisio MS; O'Dorisio TM; Zamba GK; Lynch CF
Pediatr Blood Cancer; 2011 Jan; 56(1):50-7. PubMed ID: 21108439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
